Table 4 Heart failure outcome trials completed in 2019: comparison of results vs. placebo
From: Report from the 5th cardiovascular outcome trial (CVOT) summit
| DAPA-HF [22] | |||
|---|---|---|---|
| Class and cardiovascular/renal endpoints | HR (95% CI) p-value | Event | Event rate (%) active vs. placebo group |
| Primary composite endpoint | Primary composite outcome | 16.3 vs. 21.2 | |
| Worsening heart failure or death from CV causes | 0.74 (0.65–0.85) p < 0.01 | ||
| Secondary outcome | Adverse events | No. (%) active vs. placebo group (p-value) | |
| CV death or heart-failure hospitalization | 0.75 (0.65–0.85) p < 0.001 | Renal event | 6.5 vs.7.2 (0.36) |
| Secondary outcome | Acute pancreatitis | – (–) | |
| Total no. of hospitalizations for heart failure and CV deaths | 0.75 (0.65–0.88) p < 0.001 | Diabetic ketoacidosis | 0.1 vs. 0a (–) |
| Secondary outcome | |||
| Change in KCCQ total symptom score at 8 months | 1.18 (1.11–1.26) p < 0.001 | ||
| Secondary outcome | |||
| Worsening renal function | 0.71 (0.44–1.16) | ||
| Secondary outcome | |||
| All-cause death | 0.83 (0.71–0.97) | ||
| Exploratory outcome | |||
| Cardiovascular death | 0.82 (0.69–0.98) | ||